ClinicalTrials.gg
RecruitingNCT06066801BOLBOCUpdated Nov 24, 2025

Bedside Bone Biopsy in Diabetic Foot Osteomyelitis

An interventional study of Bedside blind bone biopsy procedure in Subjects With Diabetes and DFU With a Suspicion of DFO, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Primary conditionDiabetic FootRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's title name Diabetic Foot, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Diabetic Foot with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Diabetic Foot · France.

Planned enrollment
4th of 34
320 · median 82
Started
2024
with 1 other
No phase
26 of 55
6 open now
Primary completion
2027-03
later than 5 of 11 live
Registered
50th of 55
by date
Lead sponsor
2 of 55
Assistance Publique - Hôpitaux de Paris

Among the 55 studies in Diabetic Foot with a site in France, this one is the 4th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2024, is one of 26 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 50th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

12 of the 55 studies in Diabetic Foot with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Diabetic Foot with a site in France, or all of them as a file.
02

Study summary

During their lifetime, 15 to 25% of patients with diabetes mellitus will develop a Diabetic Foot Ulcer (DFU) related to neuropathy and/or peripheral arterial disease. DFU is the leading cause of non-traumatic lower-extremity amputation worldwide. Diabetic foot osteomyelitis (DFO), which complicates up to 60% of DFU, is a major trigger of amputation in over 80% of persons with diabetes resulting in subsequent loss of quality of life. It has been shown that medical treatment of DFO may prevent amputations with early diagnosis of osteomyelitis and appropriate use of antibiotics. Empirical antimicrobial treatment is not recommended for DFO as for other chronic infections. Surgically or radiologically acquired bone sample for culture is the reference standard recommended by the International Working Group of Diabetic Foot (IWGDF) to diagnose DFO and to determine the causative bacteria and their susceptibility. However, defining appropriate antimicrobial therapy directed to the causative bacteria in DFO is challenging since it requires bone biopsy (BB) procedures which are underused in clinical practice for various reasons: lack of availability, cost, and delay. Some clinicians also find bone biopsy cumbersome or too invasive.

To overcome these barriers, we have set up for a few years a bedside blind BB procedure performed by diabetologists at the bedside in the clinical ward. Since then, this method has been used in more than 200 patients with DFO in the diabetology departments of Lariboisiere Hospital and Bichat Hospital (Paris). We have recently published our observational data of 79 patients showing that bedside BB is a simple, safe and efficient procedure for the diagnosis of DFO with a similar rate of complete healing at 12 months compared to conventional surgical or radiological bone biopsies. In order to extend and confirm these preliminary and observational results, the aim of this study is to compare the efficiency and safety of bedside BB versus conventional bone biopsy in a randomized controlled trial (RCT) of patients with DFO. Our hypothesis is that bedside BB is non-inferior to conventional bone biopsy in DFO and can be used as a simpler alternative procedure to document DFO

Read the detailed description

During their lifetime, 15 to 25% of patients with diabetes mellitus will develop a Diabetic Foot Ulcer (DFU) related to neuropathy and/or peripheral arterial disease1. DFU is the leading cause of non-traumatic lower-extremity amputation worldwide. DFO, which complicates up to 60% of DFU, is a major trigger of amputation in over 80% of persons with diabetes resulting in subsequent loss of quality of life2. It has been shown that medical treatment of DFO may prevent amputations with early diagnosis of osteomyelitis and appropriate use of antibiotics3. Empirical antimicrobial treatment is not recommended for DFO as for other chronic infections. Surgically or radiologically acquired bone sample for culture is the reference standard recommended by the International Working Group of Diabetic Foot (IWGDF) to diagnose DFO and to determine the causative bacteria and their susceptibility4. However, defining appropriate antimicrobial therapy directed to the causative bacteria in DFO is challenging since it requires bone biopsy (BB) procedures which are underused in clinical practice for various reasons including lack of availability, cost, and delay. Some clinicians also find bone biopsy cumbersome or too invasive.

To overcome these barriers, we have set up for a few years a bedside blind BB procedure performed by a physician at the bedside in the clinical ward. Since then, this method has been used in more than 200 patients with DFO in the diabetology departments of Lariboisiere Hospital and Bichat Hospital (Paris). We have recently published our observational data of 79 patients showing that bedside BB is a simple, safe and efficient procedure for the diagnosis of DFO with a similar rate of complete DFU healing at 12 months compared to conventional surgical or radiological bone biopsies6. In order to extend and confirm these preliminary and observational results, the aim of this study is to compare the efficiency and safety of bedside versus conventional BB in a randomized controlled trial (RCT) of patients with DFO. Our hypothesis is that bedside BB is non inferior to conventional BB in DFO outcomes and can be used as a simpler alternative procedure to document DFO.

The main objective is to demonstrate non-inferiority of beside blind bone biopsy compared to conventional bone biopsy (surgical or radiological) on DFO remission without surgery at 1 year.

The secondary objectives of this study are to:

  1. compare clinical efficacy between groups of bone biopsy
  2. compare microbiological culture results between groups
  3. compare the safety of both procedures
  4. compare DFO remission according to results of BB (negative or positive)

The health economic of this study are to:

  1. to estimate total costs for the intervention and total medical costs in each groups
  2. to estimate total quality adjusted life years (QALYs) based upon EQ5D5L scores
  3. to calculate the point estimate of the incremental cost utility ratio and estimate the probability of decremental cost effectiveness for the beside blind bone biopsy compared to conventional biopsy.

In this study, we will include subjects with diabetes and DFU with a suspicion of DFO. DFO is a complication of a large amount of DFU and is a major trigger of lower limb amputations. As we will include participants before bacteriological confirmation of DFO through bone biopsy, we will use the clinical and radiological criteria for DFO according to IWGDF 2019 guidelines4.

These criteria include having at least one of the following signs:

  • A positive probe to bone test and abnormalities on plain X-ray suggestive for osteomyelitis
  • Signs of osteomyelitis on CT-scan and/or MRI and/or white blood cell SPECT/CT and/or 18Fluor-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT- scan
03

Conditions studied

  • Subjects With Diabetes and DFU With a Suspicion of DFO

Browse trials for

Keywords

  • Bedside bone biopsy, conventional bone biopsy, diabetes, Diabetic Foot Ulcer (DFU), diabetic foot osteomyelitis (DFO)
04

In context

Diabetic Foot Reclassified

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's planned enrollment of 320 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study must fulfill all of the following criteria:

  • Aged >18 years
  • Diabetes mellitus
  • At least one of the following signs of osteomyelitis according to IWGDF 2019 guidelines:

A positive probe to bone test and abnormalities on plain X-ray suggestive for osteomyelitis Signs of osteomyelitis on CT-scan and/or MRI and/or white blood cell SPECT/CT and/or FDG-PET/CT-scan

- Absence of antibacterial therapy within 14 days before inclusion

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

  • Urgent need for surgery
  • Critical limb ischemia which cannot be corrected by revascularization procedure
  • Subjects that (are likely to) undergo surgical or percutaneous revascularization are not excluded
  • Antibiotic treatment in the last 15 days before bone
  • Osteomyelitis in the area of the Charcot foot destructive process
  • Unlikely to live at least 1 year
  • Not being able to give and willing to comply with the research protocol
  • Pregnant or breastfeeding women
  • Absence of affiliation to French social insurance
  • State medical aid (AME)
  • Deprivation of liberty, being under a legal protective measure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Bedside blind bone biopsy procedure

    Bedside blind bone biopsy procedure performed by a physician of the participating center through healthy skin with bone trocar following local and light systemic anesthesia. Samples will be analyzed for microbiology and histopathology

    Procedure: Bedside blind bone biopsy procedure

  • Active comparator
    Standard bone biopsy procedure

    Standard BB procedure (surgical or radiological) performed according to the local standard of care of each participating center and done through healthy skin and under locoregional anesthesia. Samples will be analyzed for microbiology and histopathology

    Procedure: Bedside blind bone biopsy procedure

Interventions

  • ProcedureBedside blind bone biopsy procedure

    It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.

07

What researchers measure

Primary outcomes

  1. the remission of DFO

    The remission of DFO at 12 months and is defined by a composite criterion as: * an epithelialized ulcer for 28 consecutive days * and absence of local inflammation and/or stabilization or improvement of radiologic abnormalities * and no need for surgery of the foot to treat DFO during follow-up

    Time frame: 12 months

Secondary outcomes

  1. Clinical efficacy

    Remission of DFO at 6 months

    Time frame: 12 months

  2. Clinical efficacy

    Need for surgery for initial DFU during follow-up

    Time frame: 12 months

  3. Clinical efficacy

    Recurrence of DFU during follow-up

    Time frame: 12 months

  4. Clinical efficacy

    Death during follow-up

    Time frame: 12 months

  5. Clinical efficacy

    Number of hospitalizations

    Time frame: 12 months

  6. Clinical efficacy

    length of hospitalizations

    Time frame: 12 months

  7. Clinical efficacy

    Length of stay of the initial hospitalization (in days)

    Time frame: 12 months

  8. Microbiological results

    Number of microorganisms per biopsy

    Time frame: 12 months

  9. Microbiological results

    Number of resistant microorganisms per biopsy

    Time frame: 12 months

  10. Microbiological results

    Total duration of the antibacterial therapy (mean in days)

    Time frame: 12 months

  11. Occurrence of adverse events during the study

    Time frame: 12 months

  12. Remission rate of DFO

    Remission rate of DFO at 12 months according to microbiological results of BB (positive or negative)

    Time frame: 12 months

  13. costs: Average costs of the biopsies

    Time frame: 1 month

  14. costs: Average total 1-year costs

    Time frame: 12 months

  15. Average 1 year QALY

    Time frame: 12 months

  16. Incremental cost effectiveness ratio

    defined as the difference in average total costs/ average total QALY

    Time frame: 12 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 36 months is above that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Mar 14, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Oct 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06066801
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Mar 14, 2024
Primary completion
Mar 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 24, 2025

Study contacts

Louis Potier, MD, PhD
Contact
louis.potier@aphp.fr
01 40 25 88 03
Louis Potier, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion